Updated 9/11/18. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
Results posted for 5 audits.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
| Celgene |
46026 59572 68817 67211 |
NJ |
No adverse findings |
None |
N/A |
| Fresenius Kabi |
63323 76045 |
IL |
No adverse findings |
None |
N/A |
| Hospira, Inc. |
00409 61703 |
IL |
No adverse findings |
None |
N/A |
| Leading Pharma, LLC |
64125 69315 |
NJ |
No adverse findings |
None |
N/A |
| Valeant Pharmaceuticals, Inc. |
00024 00066 00095 00187 00884 13548 24208 25010 30237 42702 57782 62592 62856 64455 65649 66490 67425 68012 68682 68782 99207 |
NJ |
No adverse findings |
None |
N/A |
Fecha de la última revisión: